MorphoSys AG, together with its subsidiaries, discovers, develops and commercializes therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. Its lead product candidate is Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B cell lymphoma and chronic lymphocytic leukemia. The company develops Tremfya, an antibody to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and adenomatous polyposis diseases; Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; and MOR106, an antibody for atopic dermatitis. It also develops Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of MorphoSys investigational compound tafasitamab (MOR208); and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
IPO Year: 2018
Exchange: NASDAQ
Website: morphosys.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/14/2024 | Overweight → Equal Weight | Wells Fargo | |
| 1/16/2024 | $9.19 → $10.40 | Overweight → Equal-Weight | Morgan Stanley |
| 10/13/2023 | $3.70 → $9.19 | Underweight → Overweight | Morgan Stanley |
| 9/15/2023 | $3.50 → $9.25 | Sell → Neutral | Goldman |
| 7/17/2023 | Sell → Hold | Deutsche Bank | |
| 6/16/2023 | $3.30 → $10.00 | Underweight → Overweight | JP Morgan |
| 6/16/2023 | $17.00 | Overweight | Wells Fargo |
| 5/31/2023 | Buy | UBS | |
| 1/6/2023 | Equal-Weight → Underweight | Morgan Stanley | |
| 12/16/2022 | Neutral → Sell | Goldman |
Wells Fargo downgraded MorphoSys from Overweight to Equal Weight
Morgan Stanley downgraded MorphoSys from Overweight to Equal-Weight and set a new price target of $10.40 from $9.20 previously
Morgan Stanley upgraded MorphoSys from Underweight to Overweight and set a new price target of $9.20 from $3.70 previously
Goldman upgraded MorphoSys from Sell to Neutral and set a new price target of $9.25 from $3.50 previously
Deutsche Bank upgraded MorphoSys from Sell to Hold
JP Morgan upgraded MorphoSys from Underweight to Overweight and set a new price target of $10.00 from $3.30 previously
Wells Fargo initiated coverage of MorphoSys with a rating of Overweight and set a new price target of $17.00
UBS initiated coverage of MorphoSys with a rating of Buy
Morgan Stanley downgraded MorphoSys from Equal-Weight to Underweight
Goldman downgraded MorphoSys from Neutral to Sell